Clearmind Medicine Inc. has enrolled and dosed its first patient at the Hadassah‑University Medical Center in Jerusalem, expanding the multinational Phase I/IIa trial for its oral MEAI‑based therapy, CMND‑100, to a new Israeli site.
The trial, which began in 2024, is designed to evaluate safety, tolerability, pharmacokinetics and preliminary efficacy of CMND‑100 in adults with Alcohol Use Disorder. The Hadassah site is led by Professor Joseph Caraco, Director of the Clinical Pharmacology Unit in the Department of Medicine, and joins existing sites at Johns Hopkins University, Yale School of Medicine and Tel Aviv Sourasky Medical Center.
Adding Hadassah increases Clearmind’s ability to recruit patients, diversify the study population and accelerate data collection, all of which are critical for meeting regulatory timelines and demonstrating the drug’s potential for approval. The enrollment follows positive top‑line results from the first cohort and a unanimous recommendation from the Data and Safety Monitoring Board to continue the study.
CMND‑100 is a non‑hallucinogenic MEAI (5‑methoxy‑2‑aminoindane) that acts as a selective serotonin releasing agent, targeting the 5‑HT1a, 5‑HT2a and 5‑HT2b receptors to reduce alcohol craving. The drug is part of a portfolio of 31 patents across 19 families, and it addresses a market of more than 28 million U.S. adults with AUD and annual costs exceeding $249 billion.
"We believe that dosing the first participant with CMND‑100 at Hadassah Medical Center marks yet another significant step forward in expanding our global trial footprint and accelerating our path to potentially delivering innovative treatments for AUD," said Dr. Adi Zuloff‑Shani, CEO of Clearmind Medicine.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.